Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-LIVR phase 3 study of lonafarnib/ritonavir with or without peginterferon alfa-2a in chronic hepatitis delta virus infection
2018-003167-54Phase 3Completed
- Sponsor
- Eiger BioPharmaceuticals, Inc.
- Start
- Feb 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lonafarnib, ritonavir and peginterferon alfa-2a in hepatitis D (HDV) (4 arms), sponsored by Eiger BioPharmaceuticals, Inc. Primary endpoint: Composite virologic and biochemical response at end of treatment. Started Feb 2019; status: completed.
02
Drugs
lonafarnibritonavirpeginterferon alfa-2a
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on 2018-003167-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003167-54.